Abnormal urinary coproporphyrin levels in patients infected by hepatitis C virus with or without human immunodeficiency virus. A study of 177 patients.
OBJECTIVE
Many cases of porphyria cutanea tarda have been described in association with human immunodeficiency virus (HIV) infection in young individuals. The link between hepatitis C virus (HCV) and porphyria cutanea tarda is even stronger as more than 50% of patients who have this diagnosis in Italy, France, or Spain are also infected by HCV. To study the role of viral infections on the metabolism of porphyrins, we measured the urinary porphyrin levels in patients with HIV and HCV infections.


METHODS
Survey; prospective study.


METHODS
University Hospital of Strasbourg, France.


METHODS
Sixty-one HIV-positive patients, 56 HCV-positive patients, 60 HIV- and HCV-positive patients, and 51 HIV- and HCV-negative control subjects were randomly selected. None had clinical signs of porphyria or a familial history of porphyria.


METHODS
The porphyrin-excretion profile was determined by high-performance liquid chromatography on fresh urine samples. The HIV and HCV viremias were quantified in the serum by the branched DNA assay. Measures were planned before data collection began.


RESULTS
The porphyrin-excretion profile typical of porphyria cutanea tarda was found in only 1 of 177 patients. In the remaining 176 patients, the mean coproporphyrin level was significantly raised in HCV-positive patients and even higher in patients who were HIV- and HCV-positive. The coproporphyrin level was not correlated to the alanine aminotransferase level, the CD4+ cell count, or the HCV and HIV viremias.


CONCLUSIONS
In cases of infection with HIV, HCV, or both, the development of a porphyria cutanea tarda urinary profile is a rare event (0.56% in this study), but coproporphyrin excretion is increased. This could be related to hepatic changes induced by the viruses. Our results do not support the hypothesis of a direct viral effect on the porphyrin metabolism. Infection with HIV, HCV, or both may be a major triggering factor, but is not sufficient to induce porphyria.
Cribier
B
B
Dermatology Clinic, Strasbourg University Hospital, France.
Rey
D
D
Uhl
G
G
Le Coz
C
C
Hirth
C
C
Libbrecht
E
E
Vetter
D
D
Lang
J M
JM
Stoll-Keller
F
F
Grosshans
E
E
D000293:Adolescent; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000032:analysis; D018791:CD4 Lymphocyte Count; D002851:Chromatography, High Pressure Liquid; D003306:Coproporphyrins / Q000378:metabolism / Q000652:urine*; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications / Q000201:enzymology / Q000652:urine*; D006679:HIV Seropositivity / Q000150:complications / Q000201:enzymology / Q000652:urine*; D006526:Hepatitis C / Q000150:complications / Q000201:enzymology / Q000652:urine*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017119:Porphyria Cutanea Tarda / Q000150:complications / Q000652:urine; D011166:Porphyrins / Q000378:metabolism / Q000652:urine; D011446:Prospective Studies; D014766:Viremia / Q000821:virology
D003306:Coproporphyrins; D004279:DNA, Viral; D011166:Porphyrins; D000410:Alanine Transaminase